These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
155 related items for PubMed ID: 17182025
1. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function. Barten MJ, Rahmel A, Boldt A, Dhein S, Bittner HB, Tarnok A, Mohr FW, Gummert JF. Comput Biol Med; 2007 Oct; 37(10):1367-73. PubMed ID: 17182025 [Abstract] [Full Text] [Related]
2. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients. Barten MJ, Rahmel A, Garbade J, Bold A, Bittner HB, Dhein S, Mohr FW, Gummert JF. Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162 [Abstract] [Full Text] [Related]
3. Flow cytometry-based pharmacodynamic monitoring after organ transplantation. Dieterlen MT, Eberhardt K, Tarnok A, Bittner HB, Barten MJ. Methods Cell Biol; 2011 Dec; 103():267-84. PubMed ID: 21722807 [Abstract] [Full Text] [Related]
4. Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay. Kurata Y, Kato M, Kuzuya T, Miwa Y, Iwasaki K, Haneda M, Amioka K, Watarai Y, Uchida K, Nakao A, Kobayashi T. Clin Pharmacol Ther; 2009 Sep; 86(3):285-9. PubMed ID: 19404248 [Abstract] [Full Text] [Related]
5. A novel approach in clinical immunosuppression monitoring: drug lymphocyte level. Barbari A, Masri M, Stephan A, Rizk S, Younan F. Exp Clin Transplant; 2007 Dec; 5(2):643-8. PubMed ID: 18194115 [Abstract] [Full Text] [Related]
6. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Konstandin MH, Sommerer C, Doesch A, Zeier M, Meuer SC, Katus HA, Dengler TJ, Giese T. Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236 [Abstract] [Full Text] [Related]
7. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation]. Blanchet B. Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908 [Abstract] [Full Text] [Related]
8. C2 therapeutic drug monitoring of cyclosporine is a safe and feasible method in de novo heart transplant patients. Puehler T, Goepel L, v Tschirschnitz M, Struckmeyer U, Ernst M, Ladenburger S, Schmid C, Cremer J, Hirt SW. Transplant Proc; 2007 Dec; 39(10):3329-33. PubMed ID: 18089381 [Abstract] [Full Text] [Related]
9. Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. Waiser J, Schneider M, Eljazyfer S, Slowinski T, Glander P, Einecke G, Budde K, Neumayer HH, Böhler T. Clin Immunol; 2006 Apr; 119(1):59-66. PubMed ID: 16451828 [Abstract] [Full Text] [Related]
10. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Böhler T, Nolting J, Kamar N, Gurragchaa P, Reisener K, Glander P, Neumayer HH, Budde K, Klupp J. Ther Drug Monit; 2007 Feb; 29(1):77-86. PubMed ID: 17304154 [Abstract] [Full Text] [Related]
12. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Böhler T, Waiser J, Lichter S, Schumann B, Neumayer HH, Kamar N, Budde K. Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821 [Abstract] [Full Text] [Related]
13. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031 [Abstract] [Full Text] [Related]
14. Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile. Takeda A, Horike K, Onoda H, Ohtsuka Y, Yoshida A, Uchida K, Morozumi K. Nephrology (Carlton); 2007 Apr; 12(2):197-204. PubMed ID: 17371346 [Abstract] [Full Text] [Related]
15. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Transplantation; 2008 Jan 15; 85(1):15-21. PubMed ID: 18192906 [Abstract] [Full Text] [Related]
16. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis. Umezawa Y, Ozawa A. Int J Dermatol; 2007 Jul 15; 46(7):763-6. PubMed ID: 17614813 [Abstract] [Full Text] [Related]
17. Quantification of T-cell proliferation for individualizing immunosuppressive therapy for transplantation patients. Ohdan H. Clin Pharmacol Ther; 2010 Jan 15; 87(1):23-6. PubMed ID: 20019698 [Abstract] [Full Text] [Related]
18. A prospective cross-over study comparing the pharmacokinetics of cyclosporine A and its metabolites after oral versus short-time intravenous cyclosporine A administration in pre-heart transplant patients. Lehle K, Kirchner GI, Rupprecht L, Gruber M, Birnbaum DE, Schmid FX, Preuner JG. Transplant Proc; 2007 Dec 15; 39(10):3323-8. PubMed ID: 18089380 [Abstract] [Full Text] [Related]
19. Cyclosporine pharmacological efficacy estimated by lymphocyte immunosuppressant sensitivity test before and after renal transplantation. Sugiyama K, Isogai K, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Saito N, Hirano T. J Clin Pharm Ther; 2009 Oct 15; 34(5):539-45. PubMed ID: 19744009 [Abstract] [Full Text] [Related]
20. Pharmacodynamics of T-cell function for monitoring immunosuppression. Barten MJ, Tarnok A, Garbade J, Bittner HB, Dhein S, Mohr FW, Gummert JF. Cell Prolif; 2007 Feb 15; 40(1):50-63. PubMed ID: 17227295 [Abstract] [Full Text] [Related] Page: [Next] [New Search]